Blog | Gen Re

Our Perspective

Healthy Food and Exercise Can Reduce Our Risk of Cancer

By Ross Campbell |July 03, 2018|English | Chinese

We are increasingly encouraged to be healthy. Government advice, advertising, peer pressure, and social and media messages all promote its benefits: Good health follows if we avoid sugar, quit smoking and eat less processed meat in favour of vegetables....
Read More
A Blood Test Can’t Detect Cancer, Can It?

By Andres Webersinke |February 06, 2018|English | Deutsch

We began 2018 with some promising news on cancer: A simple blood test can now detect disease in eight common sites. Called the CancerSEEK test, it was developed at the Johns Hopkins Kimmel Cancer Center, and may herald a new age in cancer medicine. How...
Read More
Stroke in Younger Adults - Have Improvements Reached Their Limit?

By Dr. Chris Ball |December 18, 2017|English

Age remains the most consistent risk factor for ischaemic stroke. Surprisingly then an estimated 10% of diagnoses are now seen in people below the age of 50. In many countries vigorous management of vascular risk coupled to improved stroke services...
Read More
Lump Sum Benefits - The Experience in New Zealand

By Li Wen Beh and Winncy Wong |November 28, 2017|English

Gen Re has conducted various experience investigations of the New Zealand Life, Disability and Critical Illness markets. Our latest survey of fully-underwritten individual Life and Trauma (Critical Illness) cover offers the first-ever insights to Total...
Read More
Progress in the Management of Multiple Sclerosis

By Dr. Chris Ball |November 23, 2017|English

Multiple Sclerosis (MS) presents a challenge to insurers due to its complex, unpredictable course. MS is a covered condition in “Critical Illness” insurance policies sold in markets across Asia, in the UK and Ireland, South Africa, New Zealand...
Read More
Genetic Testing and the Power of Knowledge

By Annika Schilling |November 16, 2017|English

Using genetic testing to make treatment decisions on serious medical conditions, such as cancer, is becoming more common. Approved tests number in the thousands, and the costs associated with genome sequencing have fallen sharply. Most genetic tests...
Read More